Alta Equipment Group (NYSE:ALTG) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.11 by 63.64 percent. This is a 800 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $405.00 million which beat the analyst consensus estimate of $379.23 million by 6.80 percent. This is a 37.29 percent increase over sales of $295.00 million the same period last year.
Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer
--Results from this ongoing, non-interventional, rollover study were presented at the 23rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company
